173 results match your criteria Jessner Lymphocytic Infiltration of the Skin


Jessner-Kanof lymphocyte infiltration responded well to impulse intralesional corticosteroid.

Dermatol Ther 2018 Nov 8;31(6):e12730. Epub 2018 Oct 8.

Department of Dermatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.

View Article
November 2018
3 Reads

Contribution of Local Analysis Techniques for the Characterization of Iron and Alloying Elements in Nitrides: Consequences on the Precipitation Process in Fe⁻Si and Fe⁻Cr Nitrided Alloys.

Materials (Basel) 2018 Aug 11;11(8). Epub 2018 Aug 11.

Institut Jean Lamour, UMR 7198, CNRS, Université de Lorraine, Campus ARTEM, 2 allée André Guinier, F-54011 Nancy CEDEX, France.

Atom Probe Tomography (APT), Transmission Electron Microscopy (TEM), and 3D mechanical calculations in complex geometry and anisotropic strain fields were employed to study the role of minor elements in the precipitation process of silicon and chromium nitrides in nitrided Fe⁻Si and Fe⁻Cr alloys, respectively. In nitrided Fe⁻Si alloys, an original sequence of Si₃N₄ precipitation was highlighted. Al⁻N clusters form first and act as nucleation sites for amorphous Si₃N₄ nitrides. Read More

View Article
August 2018
3 Reads

Jessner lymphocytic infiltration - rare in childhood.

Dermatol Online J 2017 Oct 15;23(10). Epub 2017 Oct 15.

Department of Dermatology and Allergy Centre, Odense University Hospital, Denmark.

We present a 13-year-old girl with Jessner lymphocytic infiltrate of the skin, who has suffered from the disease since the age of 9 years. It is a rare disease in childhood, and we highlight the clinical features and therapeutic response of tacrolimus. Read More

View Article
October 2017
23 Reads

A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection.

Virol J 2018 01 30;15(1):26. Epub 2018 Jan 30.

Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium.

Background: Simeprevir is approved with pegylated interferon and ribavirin (PR) for chronic hepatitis C virus (HCV) genotype (GT) 1 and GT4 infection in the USA and the European Union.

Methods: This 3-year follow-up study assessed the durability of sustained virologic response (SVR) (undetectable HCV RNA 12 or 24 weeks after treatment end), and evaluated the persistence of treatment-emergent NS3/4A protease inhibitor resistance in patients not achieving SVR following treatment with simeprevir plus PR in the parent study. The maintenance of SVR after the last post-therapy follow-up visit of the parent study (LPVPS) was assessed using HCV RNA measurements. Read More

View Article
January 2018
5 Reads

Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications.

Br J Clin Pharmacol 2018 May 21;84(5):961-971. Epub 2018 Feb 21.

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.

Aims: Direct-acting antiviral agents (DAAs) for the treatment of hepatitis C (HCV) can be associated with drug-drug interactions (DDIs) with concomitant medications. The practical clinical implications of such DDIs are poorly understood. We assessed the clinical impact of possible pharmacokinetic (PK) interactions between simeprevir and frequently prescribed concomitant medications. Read More

View Article
May 2018
4 Reads

Comparative study of buffered 50% glycolic acid (pH 3.0) + 0.5% salicylic acid solution vs Jessner's solution in patients with acne vulgaris.

J Cosmet Dermatol 2018 Oct 21;17(5):797-801. Epub 2017 Nov 21.

Department of Dermatology, CHA Bundang Medical Center, CHA University, Seongnam, Korea.

Background: Superficial chemical peels are frequently used in acne vulgaris treatment. Although glycolic acid (GA) has been widely used in clinical practice, its pH ranges from 0.08-2. Read More

View Article
October 2018
8 Reads

Q-switched Nd: YAG laser alone or with modified Jessner chemical peeling for treatment of mixed melasma in dark skin types: A comparative clinical, histopathological, and immunohistochemical study.

J Cosmet Dermatol 2018 Jun 22;17(3):319-327. Epub 2017 Oct 22.

Dermatology and leprosy Hospital, Al-Minya, Egypt.

Backgrounds: Treatment of mixed melasma remains challenging. Promising results have been achieved with low-fluence 1064-nm Q-switched Nd-YAG laser; however, multiple sessions are necessary with occurrence of complications especially in dark skin types. So, combination methods may be recommended. Read More

View Article
June 2018
3 Reads

Etanercept-Induced Lymphocytic Infiltration of Jessner-Kanof.

Arthritis Rheumatol 2018 Mar 10;70(3):449. Epub 2018 Jan 10.

Centre Hospitalier de Valenciennes, Valenciennes, France.

View Article
March 2018
16 Reads

Facial Erosive Pustular Dermatosis After Cosmetic Resurfacing.

JAMA Dermatol 2017 Oct;153(10):1021-1025

Department of Dermatology, University of Michigan Medical School, Ann Arbor.

Importance: Erosive pustular dermatosis (EPD) is a rare condition that typically affects actinically damaged skin of the scalp. Characterized by sterile pustules, erosions, and crusts, EPD is difficult to treat and heals slowly. The exact cause of EPD is unknown, although trauma is an inciting factor. Read More

View Article
October 2017
17 Reads

The Histopathological Spectrum of Pseudolymphomatous Infiltrates in Cutaneous Lupus Erythematosus.

Am J Dermatopathol 2018 Apr;40(4):247-253

Research Unit Dermatopathology, Department of Dermatology, Medical University of Graz, Graz, Austria.

The occurrence of pseudolymphomatous infiltrates in cutaneous lupus erythematosus (cLE) is described mainly in lupus panniculitis and lupus tumidus/lymphocytic infiltration of the skin (Jessner-Kanof). We collected 15 cases of pseudolymphomatous cLE other than lupus panniculitis and lupus tumidus (M:F = 4:11; age range: 23-79 years; mean age: 50.9 years; median age: 57 years). Read More

View Article
April 2018
17 Reads

Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study.

BMC Infect Dis 2017 06 2;17(1):389. Epub 2017 Jun 2.

Janssen Pharmaceutica NV, Beerse, Belgium.

Background: This Phase 3, open-label, rollover study (NCT01323244) investigated the efficacy and safety of simeprevir plus peginterferon α-2a (PegIFNα-2a) and ribavirin (RBV) in a well-characterized population of HCV genotype 1 (GT1)-infected treatment-experienced patients.

Methods: Patients who had failed PegIFNα/RBV treatment in the placebo arm of a previous Phase 2/3 simeprevir study (Phase 2/3 group, n = 125), or had been exposed to HCV direct-acting antivirals (simeprevir or other) for up to 14 days in a selected Phase 1 study (Phase 1 group, n = 16), were eligible. Phase 2/3 group patients were classified according to prior relapse, breakthrough, or non-response (null response, partial response, non-classifiable non-response) to PegIFNα/RBV. Read More

View Article
June 2017
41 Reads

Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study.

Transpl Infect Dis 2017 Jun 4;19(3). Epub 2017 May 4.

Janssen Research & Development, LLC, Titusville, NJ, USA.

Background: Recurrent hepatitis C virus (HCV) infection following liver transplantation is associated with accelerated progression to graft failure and reduced patient survival.

Methods: The Phase II, open-label SATURN study (NCT01938625) investigated the combination of simeprevir (SMV), daclatasvir (DCV), and ribavirin (RBV) administered for 24 weeks in 35 patients with recurrent HCV genotype (GT) 1b infection after orthotopic liver transplantation (OLT).

Results: High rates of both on-treatment and sustained virologic response 12 weeks after end of treatment (SVR12) were achieved in patients who were either treatment-naïve or had failed post-OLT treatment with peginterferon and RBV. Read More

View Article
June 2017
10 Reads

Chemical peels in active acne and acne scars.

Clin Dermatol 2017 Mar - Apr;35(2):179-182. Epub 2016 Oct 27.

Department of Dermatology and Venereology, Andreas Sygros Skin Hospital, Athens, Greece. Electronic address:

Chemical peeling is a widely used procedure in the management of acne and acne scars. It causes controlled destruction of a part of or the entire epidermis, with or without the dermis, leading to exfoliation and removal of superficial lesions, followed by regeneration of new epidermal and dermal tissues. The most frequently used peeling agents are salicylic acid, glycolic acid, pyruvic acid, lactic acid, mandelic acid, Jessner solution, trichloroacetic acid, and phenol. Read More

View Article
November 2017
3 Reads

Combined Jessner Solution and Trichloroacetic Acid Versus Trichloroacetic Acid Alone in the Treatment of Melasma in Dark-Skinned Patients.

Dermatol Surg 2017 May;43(5):651-656

*All authors are affiliated with the Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Assiut University, Assiut, Egypt.

Background: Melasma is a common challenging pigmentary skin disorder especially in dark-skinned females urging them to seek medical help. Many modalities of treatment are available, but none is satisfactory.

Objective: To compare safety and efficacy of combined trichloroacetic acid (TCA) (20%-25%) and Jessner's solution versus TCA (20%-25%) alone in dark patients with melasma. Read More

View Article
May 2017
4 Reads

Universal Trichloroacetic Acid Peel Technique for Light and Dark Skin.

JAMA Facial Plast Surg 2017 May;19(3):212-219

Department of Dermatology, McGill University, Montreal, Quebec, Canada.

Importance: Despite their great potential, medium and deep trichloroacetic acid peels are underused in light-skinned patients and are rarely used in darker-skinned patients because of the widespread fear of pigmentary complications and scarring. This concern has led many physicians to opt for the use of lighter types of peels (glycolic acid peel, Jessner peel, etc) and different lasers and intense light technologies. Trichloroacetic acid peels have been described in numerous publications. Read More

View Article
May 2017
2 Reads

Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO).

Aliment Pharmacol Ther 2017 02 29;45(3):468-475. Epub 2016 Nov 29.

Janssen Pharmaceutica NV, Beerse, Belgium.

Background: Hepatitis C virus (HCV) infection is a leading cause of liver cirrhosis and subsequent hepatocellular carcinoma. HCV genotype 4 is found widely in the Middle East, Egypt and Africa, and has also spread into Europe. There are limited data available regarding the use of direct-acting antiviral agents in HCV genotype 4-infected patients with cirrhosis. Read More

View Article
February 2017
8 Reads

Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study.

J Viral Hepat 2017 01 3;24(1):28-36. Epub 2016 Oct 3.

Janssen Pharmaceutica NV, Beerse, Belgium.

Simeprevir is a hepatitis C virus NS3/4A protease inhibitor. Hepatitis C virus baseline NS3/4A polymorphisms and emerging mutations were characterized in treatment-naїve and treatment-experienced genotype 4-infected patients treated with simeprevir+peginterferon/ribavirin in the RESTORE study. Population sequencing of the NS3/4A region was performed and in vitro simeprevir activity against site-directed mutants or chimeric replicons with patient-derived NS3 protease sequences was assessed in a transient replicon assay. Read More

View Article
January 2017
1 Read

Mepacrine as successful monotherapy for refractory Jessner-Kanof disease: still an important drug in the dermatologic armamentarium.

J Dermatolog Treat 2017 May 10;28(3):276-278. Epub 2016 Aug 10.

a Department of Dermatology , University Hospital Antwerp (UZA), University of Antwerp (UA) , Antwerp , Belgium.

Introduction: Jessner-Kanof disease (JKD), a lymphocytic infiltration of the skin, can be difficult to treat. Mepacrine (quinacrine), an anti-malarial less available in Belgium, may be beneficial.

Patients And Methods: Two female patients with biopsy-proven and therapy-resistant JKD, not responding to topical and systemic corticosteroids, (hydroxy-)chloroquine and/or dapsone, were treated with mepacrine 100 mg daily. Read More

View Article
May 2017
11 Reads

Nonconventional Use of Flash-Lamp Pulsed-Dye Laser in Dermatology.

Biomed Res Int 2016 18;2016:7981640. Epub 2016 Aug 18.

Laser in Dermatology Unit, University of Rome "Tor Vergata", Rome, Italy.

Flash-lamp pulsed-dye laser (FPDL) is a nonablative technology, typically used in vascular malformation therapy due to its specificity for hemoglobin. FPDL treatments were performed in a large group of patients with persistent and/or recalcitrant different dermatological lesions with cutaneous microvessel involvement. In particular, 149 patients (73 males and 76 females) were treated. Read More

View Article
February 2017
10 Reads

Jessner's solution vs. 30% salicylic acid peels: a comparative study of the efficacy and safety in mild-to-moderate acne vulgaris.

J Cosmet Dermatol 2017 Mar 25;16(1):43-51. Epub 2016 Aug 25.

Department of Dermatology, Venereology and Leprology, Pt B D Sharma University of Health Sciences, Rohtak, Haryana, India.

Introduction: Chemical peeling is a well-identified therapeutic modality for acne vulgaris (AV). Jessner's solution (JS) is a known peeling agent for acne since more than 100 years. Salicylic acid (SA) peel is a well-established peeling agent for acne. Read More

View Article
March 2017
52 Reads

Unilateral unique Lupus tumidus: pathogenetic mystery and diagnostic problem.

Wien Med Wochenschr 2016 May 13;166(7-8):250-3. Epub 2016 Jan 13.

Policlinic for Dermatology and Venereology, University Hospital Lozenetz, Koziak street 1, 1407, Sofia, Bulgaria.

Lupus tumidus is a rare immunological disorder whose pathogenesis is not fully understood. Although on the one hand there are some differences in (1) the clinical morphology of lesions, (2) the histopathology picture, as well as in (3) serological profile of lupus tumidus patients at the current moment, the disease is regarded as a subform of chronic cutaneous lupus erythematosus. Differential diagnosis requires the exclusion of many diseases such as Jessner Kanoff lymphocytic infiltration, polymorphous light eruption, and reticular erythematous mucinosis. Read More

View Article
May 2016
44 Reads

Ustekinumab-induced drug eruption resembling lymphocytic infiltration (of Jessner-Kanof) and lupus erythematosus tumidus.

Br J Clin Pharmacol 2016 Apr 29;81(4):792-4. Epub 2015 Dec 29.

Department of Clinical Experimental Medicine, Section of Dermatology, A.O.U. Policlinico 'G. Martino', University of Messina, Messina, Italy.

View Article
April 2016
3 Reads

Efficacy of Modified Jessner's Peel and 20% TCA Versus 20% TCA Peel Alone for the Treatment of Acne Scars.

Authors:
Neerja Puri

J Cutan Aesthet Surg 2015 Jan-Mar;8(1):42-5

Department of Dermatology, Punjab Health Systems Corporation, Ludhiana, Punjab, India.

Introduction: There is a paucity of studies on the use of chemical peels for acne scars among the Asian population. A trichloroacetic acid (TCA) and Jessner's combination chemical peel, originally described by Monheit, is said to be better than a TCA peel alone.

Aims: The aim of the study was to compare the efficacy of 20% TCA and Jessner's solution versus 20% TCA alone for the treatment of acne scars. Read More

View Article
May 2015
10 Reads

Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4.

J Hepatol 2015 May 14;62(5):1047-55. Epub 2015 Jan 14.

Janssen Infectious Diseases BVBA, Beerse, Belgium.

Background & Aims: Simeprevir (SMV) is a once-daily (QD), oral hepatitis C virus (HCV) NS3/4A protease inhibitor approved for treatment of genotype (GT) 1 and GT4 infection. This Phase III, open-label, single-arm study (RESTORE; NCT01567735) evaluated efficacy/safety of SMV with peginterferon-α-2a/ribavirin (PR) in patients with chronic HCV GT4 infection.

Methods: 107 patients were included. Read More

View Article
May 2015
14 Reads

Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST-1, QUEST-2 and PROMISE studies.

J Viral Hepat 2015 Aug 9;22(8):639-50. Epub 2014 Dec 9.

Janssen Research and Development, Beerse, Belgium.

The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient-reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES-D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double-blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response-guided therapy (RGT) approach. Read More

View Article

Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.

Lancet Infect Dis 2015 Jan 5;15(1):27-35. Epub 2014 Dec 5.

Janssen Infectious Diseases BVBA, Beerse, Belgium.

Background: We did a phase 3 study in previous non-responders with chronic hepatitis C virus (HCV) genotype 1 infection and compensated liver disease that related to the standard of care for these patients at the time this study was initiated. We investigated whether simeprevir is non-inferior in terms of efficacy to telaprevir, each in combination with peginterferon alfa-2a and ribavirin.

Methods: We did this randomised, double-blind, phase 3 trial at 169 investigational sites in 24 countries. Read More

View Article
January 2015
30 Reads

Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies.

J Viral Hepat 2015 Apr 3;22(4):366-75. Epub 2014 Nov 3.

Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany.

This pooled analysis of five Phase IIb and III studies evaluated the safety and tolerability of simeprevir, a once daily, oral hepatitis C virus (HCV) NS3/4A protease inhibitor. Data were summarised for patients who received simeprevir 150 mg once daily (n = 924) or placebo (n = 540) plus pegylated interferon-α/ribavirin for 12 weeks. During the first 12 weeks of treatment, few patients discontinued simeprevir or placebo due to adverse events (AEs) (both 2. Read More

View Article

Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.

Clin Infect Dis 2014 Dec 5;59(11):1579-87. Epub 2014 Sep 5.

Janssen Infectious Diseases BVBA.

Background: Simeprevir is an oral, once-daily, hepatitis C virus (HCV) NS3/4A protease inhibitor for the treatment of chronic HCV genotype 1 infection. Human immunodeficiency virus (HIV) coinfection accelerates progression of liver disease. This uncontrolled, open-label trial explored the safety and efficacy of simeprevir in patients with HCV genotype 1/HIV type 1 (HIV-1) coinfection. Read More

View Article
December 2014
23 Reads

Double threshold in bi- and multilingual contexts: preconditions for higher academic attainment in English as an additional language.

Front Psychol 2014 5;5:546. Epub 2014 Jun 5.

Department of English and American Studies, University of Hamburg Hamburg, Germany.

Bi- and multilingualism has been shown to have positive effects on the attainment of third and additional languages. These effects, however, depend on the type of bi- and multilingualism and the status of the languages involved (Cenoz, 2003; Jessner, 2006). In this exploratory trend study, we revisit Cummins' Threshold Hypothesis (1979), claiming that bilingual children must reach certain levels of attainment in order to (a) avoid academic deficits and (b) allow bilingualism to have a positive effect on their cognitive development and academic attainment. Read More

View Article

Duloxetine-induced pseudolymphoma with features of lymphocytic infiltration of Jessner-Kanof.

Acta Derm Venereol 2014 Sep;94(5):605-6

Department Medical Sciences, Section of Dermatology, University of Ferrara, Via Savonarola 9, IT-44123 Ferrara, Italy.

View Article
September 2014
15 Reads

Chemical peels: panel discussion.

Facial Plast Surg Clin North Am 2014 Feb;22(1):1-23

Cortez Facial Plastic Surgery, 14241 Metcalf Avenue, Overland Park, KS 66223, USA. Electronic address:

Edwin Cortez, Fred Fedok, and Devinder Mangat address questions for discussion and debate. Do you agree or disagree, and why, with the following: "The best method to improve moderate to deep rhytids is the croton oil-phenol peel." "There are no problems with cardiotoxicity with croton oil-phenol peels if done appropriately. Read More

View Article
February 2014
18 Reads

A comparative study of low-fluence 1,064 nm Q-Switched Nd:YAG laser with or without chemical peeling using Jessner's solution in melasma patients.

J Cosmet Laser Ther 2014 Dec 19;16(6):264-70. Epub 2014 Sep 19.

Department of Dermatology, Ulsan University Hospital , Ulsan , Republic of Korea.

Background: Although low-fluence 1,064-nm Q-switched Nd:YAG laser (QSNYL) is widely used for the treatment of melasma, multiple treatments are necessary for clinical improvement. Superficial chemical peeling using Jessner's solution has been used for treatment of melasma conventionally.

Objectives: To evaluate the additional therapeutic effect and adverse effects of Jessner's peel when combined with 1,064 nm QSNYL for melasma patients in a double-blind, placebo-controlled design. Read More

View Article
December 2014
4 Reads

Josef jadassohn--an appreciation on the occasion of his 150th birthday.

Authors:
Wolfgang Weyers

Am J Dermatopathol 2013 Oct;35(7):742-51

Center for Dermatopathology, Freiburg, Germany.

Josef Jadassohn was a pioneering dermatologist who influenced the development of his specialty in many ways. He introduced the patch test for detection of hypersensitivity reactions, gave original descriptions of several entities, such as nevus sebaceous, granulosis rubra nasi, and pachyonychia congenita, and edited the Handbuch der Haut- und Geschlechtskrankheiten, the most comprehensive textbook of dermatology ever published. Moreover, Jadassohn left a phalanx of distinguished students, including Felix Lewandowsky, Wilhelm Lutz, Max Jessner, Hans Biberstein, Hermann Pinkus, and Marion B. Read More

View Article
October 2013
14 Reads

Jessner-Kanof disease: two effective and sure therapeutic options.

Dermatol Ther 2013 Jul-Aug;26(4):373-6

Department of Critical Care Medicine and Surgery, Division of Dermatology, University of Florence, Florence, Italy.

Jassner-Kanof disease is a benign cutaneous disorder clinically characterized by recurrent asymptomatic erythematous papules and plaques sometimes grouped with an arciform disposition on the face, neck, and back. We describe a case of Jassner-Kanof disease resistant to conventional therapy, in which the lesions located on the arms were treated with 595 nm pulsed dye laser, and those on the trunk underwent a treatment with tacrolimus 0.03% ointment. Read More

View Article
April 2014
5 Reads

[Current therapeutic indications of thalidomide and lenalidomide].

Med Clin (Barc) 2014 Apr 3;142(8):360-4. Epub 2013 Jul 3.

Servicio de Clínica Médica, Hospital Provincial del Centenario, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Rosario, Argentina.

Thalidomide is a synthetic glutamic acid derivative first introduced in 1956 in Germany as an over the counter medications. It was thought to be one of the safest sedatives ever produced as it was effective in small doses, was not addictive, and did not have acute side-effects such as motor impairment, but was quickly removed from market after it was linked to cases of severe birth defects. The Food and Drug Administration approved use in the treatment of erythema nodosum leprosum. Read More

View Article
April 2014
4 Reads

The efficacy of pulsed dye laser treatment for inflammatory skin diseases: a systematic review.

J Am Acad Dermatol 2013 Oct 24;69(4):609-615.e8. Epub 2013 May 24.

Department of Dermatology, Amphia Hospital Breda, Breda, The Netherlands. Electronic address:

Background: The position of the pulsed dye laser (PDL) in the treatment of inflammatory skin diseases is still unclear. Evidence-based recommendations are lacking.

Objectives: We sought to systematically review all available literature concerning PDL treatment for inflammatory skin diseases and to propose a recommendation. Read More

View Article
October 2013
3 Reads

[Palpable arciforme migratory erythema].

Hautarzt 2012 Dec;63(12):965-8

Klinik für Dermatologie, Allergologie und Phlebologie, Klinikum Bremerhaven Reinkenheide, Postbrookstr. 103, 27574, Bremerhaven, Deutschland.

A 39-year-old man presented with an annular clearly palpable erythema on the décolleté. Based on clinical and histopathological findings, palpable migratory arciform erythema was diagnosed. This skin condition is classified as a rare type of T-cell pseudolymphoma. Read More

View Article
December 2012
7 Reads

Jessner lymphocytic infiltrate as a side effect of bee venom immunotherapy.

J Investig Allergol Clin Immunol 2012 ;22(4):308-9

Allergy and Clinical Immunology Unit, Antalya Education and Training Hospital, Antalya, Turkey.

View Article

Jessner lymphocytic infiltrate presenting on a cutaneous leishmaniasis scar: case report.

Authors:
G Sadeghian H Ziaei

East Mediterr Health J 2012 May;18(5):537-8

Skin Disease and Leishmaniasis Research Centre, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran.

View Article

Photodynamic therapy: new treatment for refractory lymphocytic infiltration of the skin.

Clin Exp Dermatol 2012 Apr 2;37(3):235-7. Epub 2012 Feb 2.

Department of Dermatology, Chung-Ang University College of Medicine, Seoul, South Korea.

Lymphocytic infiltration of the skin (LIS) is a relatively uncommon skin condition, first described by Jessner and Kanof in 1953. LIS presents mainly on the face, in particular on the cheeks and earlobe, but also on the neck, upper trunk or proximal limbs of middle-aged adults. LIS is often resistant to treatment. Read More

View Article
April 2012
3 Reads

Familial benign chronic pemphigus (Hailey-Hailey Disease): use of topical immunomodulators as a modern treatment option.

Rev Med Chil 2011 May 16;139(5):633-7. Epub 2011 Sep 16.

Department of Dermatology and Venereology, Medical Faculty, Trakian University of Stara Zagora, Bulgaria.

Benign chronic familial pemphigus (Hailey-Hailey disease) is a rare autosomal dominant blistering skin disorder characterized by suprabasal cell separation (acantholysis) of the epidermis. The Hailey brothers first described it in 1939. Hailey-Hailey disease usually appears in the third or fourth decade, although it can occur at any age. Read More

View Article
May 2011
14 Reads
1 Citation
0.370 Impact Factor

[An atypical presentation of primary cutaneous diffuse B-cell lymphoma, leg type].

Ann Dermatol Venereol 2011 Aug-Sep;138(8-9):601-4. Epub 2011 Apr 23.

Service de dermatologie, hôpital Fournier, CHU de Nancy, 36, quai de la Bataille, 54035 Nancy cedex, France.

Background: Primary cutaneous diffuse B-cell lymphoma, leg type, are rare and aggressive tumours frequently affecting elderly patients. We present a case of a 53-year-old woman with an atypical presentation of primary cutaneous diffuse B-cell lymphoma, leg type.

Case Report: Eight years after complete excision of a Jessner-Kanof lymphocytic infiltration on the right shoulder, the patient developed a primary cutaneous diffuse B-cell lymphoma, leg type at the same site. Read More

View Article
January 2012
2 Reads

[Lupus erythematosus tumidus: a clinical entity still being defined].

Actas Dermosifiliogr 2011 Nov 27;102(9):668-74. Epub 2011 Jul 27.

Servicio de Dermatología, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.

Lupus erythematosus tumidus (LET), a form of cutaneous lupus erythematosus that was described some years ago, has begun to receive more attention in the past decade as many published studies have helped to define the particularities of this subtype.The clinical features of LET include the absence of changes on the surface of the epidermis (such as erosion, atrophy, scaling, or follicular plugging) and the lack of scarring on resolution.Because flares are easily induced on exposure to sunlight, eruptions tend to occur in episodes. Read More

View Article
November 2011

[Pulsed dye laser treatment for Jessner's lymphocytic infiltration of the skin].

Authors:
J-L Michel D Perrin

Ann Dermatol Venereol 2010 Dec;137(12):803-7

Cabinet de Dermatologie, Avenue Résidence v, 14, Place des Grenadiers-quartier-grouchy, 42000 Saint-Étienne, France.

Background: Jessner's lymphocytic infiltration of the skin (LIS) is a chronic, benign T-cell infiltrative disorder, usually manifesting as erythematous papules or plaques on the face, neck and back.

Patients And Methods: five patients presented LIS with numerous skin lesions on the face and back characteristic of this disease. Histological examination showed a lymphocytic infiltrate in the dermis without any modification of the epidermis. Read More

View Article
December 2010
5 Reads

Innovative uses of thalidomide.

Dermatol Clin 2010 Jul;28(3):577-86

Department of Dermatology, Baylor College of Medicine, BCM Debakey Building M220, One Baylor Plaza, Mail Stop BCM368, Houston, TX 77030, USA.

Thalidomide is approved for treating erythema nodosum leprosum and multiple myeloma, but it has also emerged as a useful treatment option for many refractory dermatologic disorders. Some of the innovative but off-label uses of thalidomide include aphthous stomatitis, Behçet's disease, lupus erythematosus, prurigo nodularis, sarcoidosis, actinic prurigo, graft-versus-host disease, Langerhans cell histiocytosis, erythema multiforme, lichen planus, Kaposi sarcoma, Jessner lymphocytic infiltrate, uremic pruritus, pyoderma gangrenosum, scleroderma, scleromyxedema, and necrobiosis lipoidica. This article reviews the background, pharmacology, and innovative uses of thalidomide in dermatology. Read More

View Article
July 2010
3 Reads

A study comparing chemical peeling using modified Jessner's solution and 15% trichloroacetic Acid versus 15% trichloroacetic acid in the treatment of melasma.

Indian J Dermatol 2009 ;54(1):41-5

Department of Dermatology, Cairo University, Cairo, Egypt.

Background: Melasma is a symmetric progressive hyperpigmentation of the facial skin that occurs in all races but has a predilection for darker skin phenotypes. Depigmenting agents, laser and chemical peeling as classic Jessner's solution, modified Jessner's solution and trichloroacetic acid have been used alone and in combination in the treatment of melasma.

Objectives: The aim of the study was to compare the therapeutic effect of combined 15% Trichloroacetic acid (TCA) and modified Jessner's solution with 15% TCA on melasma. Read More

View Article